An earlier version of this live blog misstated the start date for Ziopharm's planned phase III drug study. It will start in mid-2010, not mid-2011. TheStreet regrets the error.

CHICAGO ( TheStreet) --Welcome to TheStreet's live-blog coverage of the American Society of Clinical Oncology (ASCO) annual meeting. It's Monday, which means the big focus will be on how ASCO-related stocks react once trading opens.

Sunesis Pharmaceuticals ( SNSS), Ziopharm Oncology ( ZIOP) and Cyclacel Pharmaceuticals ( CYCC) will be among the companies also presenting data today.

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on all the investor-worthy buzz. With my iPhone and some nifty software, I'll even try to bring you photos and audio for an even deeper perspective of what's happening at ASCO 2010.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits. You can also follow my ASCO 2010 coverage on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

WATCH: 4 Experts Lay Out How Wealthy Investors Should Play Today's Risky Market

WATCH: 4 Experts Lay Out How Wealthy Investors Should Play Today's Risky Market

These 5 Autonomous Driving Stocks Are Flashing Buy Signals

These 5 Autonomous Driving Stocks Are Flashing Buy Signals

Facebook CEO Mark Zuckerberg Appears Before European Parliament

Facebook CEO Mark Zuckerberg Appears Before European Parliament

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer: Wabtec Deal Gives General Electric Optionality

Jim Cramer: Wabtec Deal Gives General Electric Optionality